Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials.
Two double-blind studies comparing the effectiveness of the cyclic nucleotide-altering agent (4-[3-butoxy-4-methoxybenzyl]-2-imidazolidinone) (Ro 20-1724) vs vehicle have demonstrated that this compound can improve psoriatic lesions. Although Ro 20-1724 was not as effective as intensive occlusive treatment of psoriatic lesions with 0.025% triamcinolone acetonide, Ro 20-1724 had no adverse systemic or cutaneous effects. Ro 20-1724 and other cyclic nucleotide-altering agents may have therapeutic potential in the future treatment of psoriasis.
D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
D007093:Imidazoles; D010919:Placebos; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D014222:Triamcinolone Acetonide